Tetrapeptide selective μ1-opioid receptor agonists – the missing link in the treatment of chronic pain in oncology?

Chronic pain syndrome remains one of the major unresolved problems in oncology: some patients continue to experience breakthrough pain, insufficient response to therapy, opioid-related adverse effects, reduced treatment adherence, tolerance, and opioid phobia. In this context, new analgesics with high efficacy and a more favorable safety profile are of particular interest. Taphalgin, a domestic tetrapeptide selective μ1-opioid receptor agonist, differs from classical opioids by lacking interaction with μ2-receptors, which may reduce the risk of adverse effects such as respiratory depression, impaired gastrointestinal motility, euphoria, and miosis. In phase II and III clinical trials, as well as in individual clinical observations, the drug demonstrated a pronounced analgesic effect in chronic cancer pain, comparable to that of morphine, with a lower incidence of adverse events and the possibility of long-term use without signs of significant tolerance or dependence. Selective peptide opioid receptor agonists may be regarded as a promising direction in the treatment of chronic pain in oncology, especially in cases of intolerance, insufficient efficacy, or limitations associated with the use of traditional opioid analgesics. Aim. To analyze the challenges in managing chronic pain syndrome in cancer patients and to evaluate the prospects of using selective tetrapeptide agonists of μ1-opioid receptors, using tafalgin as an example, taking into account its pharmacological features, clinical trial results, and real-world clinical practice experience.

Authors

Publication Details

Journal
Head and neck tumors (HNT)
Published
2026-11-20
DOI
https://doi.org/10.17650/2222-1468-2026-16-3-76-86
Primary Topic
Pain Management and Opioid Use
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tetrapeptide selective μ1-opioid receptor agonists – the missing link in the treatment of chronic pain in oncology?

A. A. Ivanov
Head and neck tumors (HNT)
Pain Management and Opioid Use
article

Tetrapeptide selective μ1-opioid receptor agonists – the missing link in the treatment of chronic pain in oncology?

A. A. Ivanov
article en

Abstract

Chronic pain syndrome remains one of the major unresolved problems in oncology: some patients continue to experience breakthrough pain, insufficient response to therapy, opioid-related adverse effects, reduced treatment adherence, tolerance, and opioid phobia. In this context, new analgesics with high efficacy and a more favorable safety profile are of particular interest. Taphalgin, a domestic tetrapeptide selective μ1-opioid receptor agonist, differs from classical opioids by lacking interaction with μ2-receptors, which may reduce the risk of adverse effects such as respiratory depression, impaired gastrointestinal motility, euphoria, and miosis. In phase II and III clinical trials, as well as in individual clinical observations, the drug demonstrated a pronounced analgesic effect in chronic cancer pain, comparable to that of morphine, with a lower incidence of adverse events and the possibility of long-term use without signs of significant tolerance or dependence. Selective peptide opioid receptor agonists may be regarded as a promising direction in the treatment of chronic pain in oncology, especially in cases of intolerance, insufficient efficacy, or limitations associated with the use of traditional opioid analgesics. Aim. To analyze the challenges in managing chronic pain syndrome in cancer patients and to evaluate the prospects of using selective tetrapeptide agonists of μ1-opioid receptors, using tafalgin as an example, taking into account its pharmacological features, clinical trial results, and real-world clinical practice experience.

Head and neck tumors (HNT)Vol. 16(3)
Pain Management and Opioid Use
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon